[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596673":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":25,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":25,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":25,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Ioannina","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nimodipine","EXPERIMENTAL","Prepared (coded) by the pharmacy 50 ml solutions of nimodipine (2 mg\u002F10 ml) with blinded 50 ml syringes will be used in each patient.",[13],"Drug: Nimodipine",{"label":15,"type":16,"description":17,"interventionNames":18},"Isotonic saline","PLACEBO_COMPARATOR","Prepared (coded) by the pharmacy 50 ml solutions with blinded 50 ml syringes of isotonic saline will be used in each patient.",[19],"Drug: Isotonic Saline",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","A continuous dose of 4 mg\u002Fh (20 ml\u002Fh) of nimodipine solution will be administered continuously 1 h prior to start of operation until 1 h after start of the procedure. • The nimodipine dose will be then reduced to 2 mg\u002Fh (10 ml\u002Fh) until 24 hrs after the end of the procedure.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Isotonic Saline","A continuous dose of 20 ml\u002Fh of normal saline solution will be administered continuously one (1) h prior to start of operation until 1 h after start of the procedure. The normal saline dose will be then reduced to 10 ml\u002Fh until 24 h after the end of the procedure.",[15],[31],{"name":32,"affiliation":33,"role":34},"Petros Tzimas, MD, PhD","University of Ioannina, Greece","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Maria-Theodora Filou, MD","CONTACT","00306948127570","marilizafilou@gmail.com",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Ourania Patroni, MD","00302613601673","patronirania@gmail.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"St. Andrews General Hospital of Patras, GREECE","RECRUITING","Pátrai","Achaea","263 32","Greece","GR",{"type":55,"coordinates":56},"Point",[57,58],21.73508,38.2462,{"lat":58,"lon":57},[61,63],{"name":37,"role":38,"phone":62,"phoneExt":25,"email":40},"0306948127570",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},{"type":34,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Petros Tzimas","Professor of Anesthesiology","100596673","perioperative-intravenous-nimodipine-trial-100596673",false,"NCT07048522","Perioperative Intravenous Nimodipine Trial","Perioperative Nimodipine for Intra- and Postoperative Pain Management and Reduction of Anesthetic Requirements in Patients Undergoing Open Colectomy: a Prospective, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled for open surgical treatment of bowel cancer at the General Hospital of Patra\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years, \\> 75 years\n* American Society of Anesthesiologists (ASA) physical status \\> III\n* Allergy to nimodipine\n* Inability to provide informed consent\n* Known severe renal insufficiency\n* Known severe bradyarrhythmia\n* Daily opioid consumption the last 7 days before surgery\n* Pain intensity assessed using the Numerical Rating Scale (NRS; 0-10), with scores greater than 5 reported on more than half of the days during the past month.","ALL","18 Years","75 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82],"NA","The role of perioperative IV administration of nimodipine, an L-type calcium channel antagonist which is capable of crossing the blood-brain barrier, on peri-operative opioid and anesthetics requirements, pain intensity, opioid-related side effects and early postoperative bowel mobility in patients undergoing surgical treatment for bowel cancer with open radical colectomy remains scarcely explored. A prospective double-blind, randomized controlled trial investigating the effect of perioperative IV administration of nimodipine in patients undergoing open colectomy for cancer treatment is therefore conducted.",[85,86,87,88,89],"Colectomy","Open Surgery","Pain","Pain, Postoperative","Pain, Acute","2025-06-30",{"date":92,"type":93},"2025-07-02","ACTUAL",{"date":95,"type":93},"2025-05-19",{"date":97,"type":79},"2027-02-15",{"name":5,"class":6},1]